NP2

AcronymDefinition
NP2Neuronal Pentraxin 2
NP2Nucleoside Phosphorylase-2
References in periodicals archive ?
The Phase II study has been designed to evaluate NP2 Enkephalin for the treatment of severe and chronic cancer pain.
In January, Diamyd Medical said it had dosed the first patient in a phase II randomised, double-blind, placebo-controlled trial with NP2 Enkephalin, which is expected to enrol a total 32 patients at about 10 sites in the USA.
The first stage of development includes design and fabrication of one Trainer and one Fighter, NP1 and NP2 respectively, along with a Shore Based Test Facility (SBTF) at Goa.
17 January 2011 - Swedish pharmaceutical company Diamyd Medical AB (STO: DIAM-B) said today it has dosed the first subject in a Phase II clinical trial in the USA evaluating the ability of the candidate drug NP2 Enkephalin to reduce cancer pain.
NP2 Enkephalin has shown substantial and sustained reduction in pain scores in a phase I clinical trial aimed at testing the safety of the product.
The purpose of the randomized, double-blind, and placebo-controlled Phase II study is to evaluate the effect of intradermal injection of NP2 Enkephalin on pain reported by subjects suffering from severe intractable pain due to cancer, as well as to confirm the safety of the treatment.
Diamyd said that the encouraging results of the Phase I trial investigating NP2 Enkephalin as a potential therapy for chronic pain, has allowed it to rapidly initiate this new study in cancer patients with chronic severe pain.
19 Otober 2010 - Sweden-based biopharmaceutical company Diamyd Medical AB (STO: DIAM) reported today substantial and sustained pain reduction in the middle and high dose cohorts of Diamyd Medical's Phase I, open-label, dose escalation trial investigating NP2 Enkephalin as a potential therapy for chronic pain.
The study and the analysis of the data is still ongoing and it is yet too early to determine what the best way forward is for the development of NP2 Enkephalin and the NTDDS platform respectively.
To verify the positive outcome of the programme, Diamyd Medical plans a multi-center placebo controlled phase II proof-of-concept study with NP2 Enkephalin in the USA.
14 September 2010 - Swedish biotech company Diamyd Medical AB (STO: DIAM B) is in talks with a number of potential partners regarding the development of its product NP2 against cancer pain, CEO Elisabeth Lindner told yesterday news agency Bloomberg.
The purpose of the Phase II study is to evaluate NP2 Enkephalin for the treatment of severe and chronic cancer pain.